MCM
IBB icon

Mainstream Capital Management’s iShares Biotechnology ETF IBB Stock Holding History

Mainstream Capital Management’s Portfolio IBB Stock Details IBB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$205K Buy
+1,076
New +$185K 0.12% 89
2025
Q1 		– Sell
-1,132
Closed -$150K – 176
2024
Q4 		$150K Buy
+1,132
New +$159K 0.1% 96

Other funds holding IBB

GIC
Generali Investments CEE Prague, Czech Republic $2.11B AUM 25.53% 1-Year Est. Return
IHL
Investment House LLC Redondo Beach, California $1.92B AUM 25.81% 1-Year Est. Return
FNFDCM
Folger Nolan Fleming Douglas Capital Management Washington, District of Columbia $1.22B AUM 34.81% 1-Year Est. Return
AC
Apella Capital West Hartford, Connecticut $7.08B AUM 17.38% 1-Year Est. Return
RFA
Reyes Financial Architecture San Diego, California $179M AUM 31.17% 1-Year Est. Return
IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return
DC
Davenport & Co Richmond, Virginia $20.4B AUM 18.11% 1-Year Est. Return
JMFC
J.M. Forbes & Co Boston, Massachusetts $1.27B AUM 26.46% 1-Year Est. Return
TFA
Toth Financial Advisory Leesburg, Virginia $1.02B AUM 28.36% 1-Year Est. Return
NRS
Neville Rodie & Shaw New York $1.55B AUM 46.95% 1-Year Est. Return

Mainstream Capital Management's IBB Position: Q2 2026 in Review

Mainstream Capital Management opened a new position in iShares Biotechnology ETF (IBB) in Q2 2026: 1,076 shares worth $205K. The stake represents 0.12% of the portfolio and ranks #89 among its holdings. This is a return to the name: Mainstream Capital Management previously reported a position in IBB as recently as Q4 2024.

Mainstream Capital Management first reported a position in IBB in Q4 2024 and has held it in 2 quarters since. 185 funds tracked by Wall St. Rank hold IBB as of Q2 2026.

  • Mainstream Capital Management held 1,076 shares of iShares Biotechnology ETF worth $205K as of Q2 2026.
  • iShares Biotechnology ETF was a new Mainstream Capital Management position in Q2 2026.
  • iShares Biotechnology ETF made up 0.12% of Mainstream Capital Management's portfolio in Q2 2026, its #89 holding.
  • Mainstream Capital Management first reported a position in iShares Biotechnology ETF in Q4 2024 and has held it in 2 quarters since.
  • 185 funds tracked by Wall St. Rank held iShares Biotechnology ETF as of Q2 2026.

Based on Mainstream Capital Management's 13F filing for Q2 2026, filed 15 Jul 2026.